Jessica Bosch fosters students’ love of science through the Illumina Genomic Discoveries program
From a young age, Jessica Bosch knew she wanted to be a biology teacher. She always loved science, competing in science fairs in middle and high school. After high school, she went on to study cell molecular biology at San Diego State University and spent eight years in drug discovery research at biotech companies. But as much as she loved the science and lab-based work, she knew it was time to transition her passion and expertise into teaching.
Cancer screening gains momentum with $99 million in funding and the country’s largest liver cancer cohort study
Jun Zhou is determined to make an impact on early cancer detection in China. The CEO of Berry Oncology, a subsidiary of Berry Genomics, is overseeing China’s first and only large-scale, forward-looking cohort study of early liver cancer screening based on next-generation sequencing (NGS) technology. It is also one of the largest and fastest-growing prospective cohort studies of liver cancer in the world.
On August 13, Illumina Shanghai Family Open Day was held in Illumina’s Shanghai office. Over 160 colleagues and families joined the fun summer party!
The office, where Illumina employees meet for daily meetings, trainings, and experiments, was decorated for adults and kids to unleash imagination and creativity.
In addition to a series of fun STEM activities and games, the kids put on lab coats and goggles to experience life as a scientist. Employee volunteers conducted a banana DNA extraction experiment and the kids visited the lab to experience the wonders of DNA!
GRAIL will remain a separate and independent unit, pending ongoing regulatory and legal review
SAN DIEGO, August 19, 2021 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) announced that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission's ongoing regulatory review.
In the future, what if you could sequence your cancer patients by the thousands, provide answers quicker, and deliver more effective treatment and better care—on a routine basis? For Providence, the nation’s third largest not-for-profit health system, that future is the present.
Next-generation sequencing is helping Native nations with sovereignty and genetic research
International Day of World’s Indigenous Peoples is celebrated each year on August 9. On this day, people from around the world are encouraged to spread the United Nation’s message on the protection and promotion of the rights of indigenous peoples. This year, Illumina is honored to highlight one of their nonprofit partners, and recent donation recipient, Native BioData Consortium (NBDC).
SAN DIEGO, August 4, 2021 /3BL Media/ - Illumina, Inc. (NASDAQ: ILMN) has donated $1 million in sequencing capabilities to the Molecular Diagnostic Reference Laboratory at Kasturba Hospital, in the Municipal Corporate of Greater Mumbai, to help expand SARS-CoV-2 sequencing capabilities in the region and support the broader genomic surveillance effort across India. Kasturba Hospital was the first hospital in Mumbai to begin sequencing SARS-CoV-2 this year and will examine how variants of the virus are being spread across India.
There are nearly 7,000 types of rare diseases, and about 80 percent of them are caused by genetic mutations. “Compared with common diseases, rare diseases are difficult to diagnose from the very beginning,” says Yiou Wang, Founder of the Illness Challenge Foundation.